Esposito Pamela 4

What Happened

• Pamela Esposito, a director of Kymera Therapeutics (KYMR), exercised stock options on 2026-05-19 to acquire 1,000 shares at $31.20 per share, for a cash outlay of $31,200. The Form 4 also reports a simultaneous disposition of 1,000 shares described as a derivative with $0.00 proceeds. The filing does not report any open‑market sale of shares for cash.

Key Details

• Transaction date: 2026-05-19 (filing date 2026-05-19)
• Exercise: 1,000 shares acquired at $31.20 each — total $31,200 (transaction code M)
• Disposition: 1,000 shares reported as a derivative disposed at $0.00 (transaction code M)
• Footnote: F1 — the shares underlying the option were fully vested and exercisable
• Shares owned after transaction: Not specified in the provided excerpt of the filing
• Timeliness: Filing and report date are the same (no late filing indicated in available data)

Context

• This was an option exercise (not an open‑market purchase or sale). The separate line showing a $0.00 derivative disposition is noted in the filing but not explained; such lines can reflect conversions, transfers, or internal adjustments rather than a cash sale. The filing contains no 10b5-1 plan, tax‑withholding detail, or other explanatory footnotes in the provided excerpt.